Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook_2014     Display Documents



ID: 682151.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook_2014
Pulmonary hypertension in chronic lung diseases
Authors:Seeger, W.; Adir, Y.; Barbera, J. A.; Champion, H.; Coghlan, J. G.; Cottin, V.; De Marco, T.; Galie, N.; Ghio, S.; Gibbs, S.; Martinez, F. J.; Semigran, M. J.; Simonneau, G.; Wells, A. U.; Vachiery, J. L.
Date of Publication (YYYY-MM-DD):2013-12-24
Journal Abbrev.:J Am Coll Cardiol
Volume:62
Issue / Number:25 Suppl
Start Page:D109
End Page:16
Audience:Not Specified
Abstract / Description:Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1 PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP >/=25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP >/=35 mm Hg or mPAP >/=25 mm Hg with low cardiac index [CI <2.0 l/min/m(2)]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlying the limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.
Free Keywords:Animals; Chronic Disease; Humans; Hypertension, Pulmonary/*diagnosis/epidemiology/*therapy; Lung Diseases, Interstitial/*diagnosis/epidemiology/*therapy; Pulmonary Disease, Chronic Obstructive/*diagnosis/epidemiology/*therapy; Pulmonary Fibrosis/diagnosis/epidemiology/therapy
External Publication Status:published
Document Type:Article
Communicated by:Svea Hümmer
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology, Haifa, Israel. Hospital Clinic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases, Barcelona, Spain. UPMC Montefiore Hospital, Pittsburgh, Pennsylvania. Department of Cardiology, Royal Free Hospital, London, United Kingdom. Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA, Lyon, France. University of California San Francisco, San Francisco, California. Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital, Bologna, Italy. Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital, London, United Kingdom. Division of Pulmonary and Critical Care, University of Michigan Medical Center, Ann Arbor, Michigan. Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital, Boston, Massachusetts. Centre National de Reference des Maladies Vasculaires Pulmonaires, Universite Paris-Sud, Hopital Antoine Beclere, Clamart, France. Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom. Department of Cardiology, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium.
Identifiers:ISSN:1558-3597 (Electronic) 0735-1097 (Linking) %R 10.1016/j.jacc.2013.10.036
URL:http://www.ncbi.nlm.nih.gov/pubmed/24355635
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.